<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692104</url>
  </required_header>
  <id_info>
    <org_study_id>H17-02634</org_study_id>
    <nct_id>NCT03692104</nct_id>
  </id_info>
  <brief_title>US-CT Fusion for Post Implant Dosimetry</brief_title>
  <official_title>Comparison Between Postoperative Ultrasound-CT Fusion With MRI-CT Fusion for Postimplant Dosimetry for Prostate LDR Permanent Seed Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post implant dosimetry is an essential part of quality assurance after permanent seed
      prostate brachytherapy. CT imaging is the standard of assessment but due to contouring
      uncertainties, MR-CT fusion is preferred. This is not always available due to financial
      restrictions. This study explores the possibility of post implant US-CT fusion to improve
      contouring accuracy and potentially replace the use of MR-CT fusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      25 participants undergoing permanent seed prostate brachytherapy will be approached to
      undergo collection of prostate US images at the completion of their procedure. This will add
      approximately 5 minutes to the duration of their brachytherapy procedure. The US study will
      not entail any discomfort or risk to participants as they are still under anesthesia for the
      implant procedure. The institution standard of care for quality assurance will be complied
      with, obtaining a CT and MRI of the prostate at 30 days after the procedure. These will be
      co-registered and analyzed in the normal fashion. In addition, the post implant US images
      will also be co-registered with the CT and the resulting dosimetric parameters compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of prostate dosimetry assessed by US-CT fusion with respect to the standard MR-CT fusion</measure>
    <time_frame>1 month</time_frame>
    <description>Dosimetry will be calculated using 2 different imaging modalities (US vs MRI) and compared</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of prostate volume assessed by 2 different imaging modalities</measure>
    <time_frame>1 month</time_frame>
    <description>Assessment of prostate volume as contoured on US vs MRI post implant</description>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>transrectal ultrasound</intervention_name>
    <description>Use of US for post implant quality assessment</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients undergoing prostate brachytherapy for localized prostate cancer.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  localized prostate cancer suitable for permanent seed implant brachytherapy as either
             monotherapy or as a boost

        Exclusion Criteria:

          -  Unable to undergo MRI
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Bachand, MD</last_name>
    <role>Study Chair</role>
    <affiliation>BC Cancer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BC Cancer</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>British Columbia Cancer Agency</investigator_affiliation>
    <investigator_full_name>Juanita Crook</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>brachytherapy</keyword>
  <keyword>Quality assurance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

